AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 12:57:29 2026-05-28 EDT			5-day change	1st Jan Change
1.120 ^USD	-.--%		-.--%	-22.76%

07-13	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
07-10	AB Science streamlines its portfolio and refocuses on two molecules

Market Cap	44.65M 50.96M 41.45M 38.09M 71.77M 4.92B 72.83M 494M 193M 2.41B 191M 187M 8.31B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	44.65M 50.96M 41.45M 38.09M 71.77M 4.92B 72.83M 494M 193M 2.41B 191M 187M 8.31B	EV / Sales 2026 *	37.2x	EV / Sales 2027 *	34.3x
Free-Float	63.24%	Yield 2026 *	-	Yield 2027 *	-

07-13	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
07-10	AB Science streamlines its portfolio and refocuses on two molecules
07-10	AB Science SA Provides Update on Clinical Program, Suspends Non-Priority Clinical Trials and Focuses on Ab8939 and Masitinib Programs	CI
07-08	Stéphane Ledermann takes the helm at AB Science as CEO
07-06	AB Science S.A. Announces Board Changes	CI
07-06	AB Science S.A. Announces CEO Changes	CI
07-02	AB Science S.A. announced that it has received $2.01616 million in funding	CI
07-01	AB Science, successful private placement
06-30	AB Science S.A. announced that it has received ?2.294 million in funding	CI
06-29	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia	CI
06-29	AB Science completes Step 3 of a Phase 1 study
06-18	AB Science Secures US Patent for Prostate Cancer Therapy	MT
06-18	AB Science Secures New U.S. Patent for Masitinib

07-10	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs	GL
07-08	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development	PU
07-01	AB Science announces the successful completion of a EUR 2.3 million private placement	GL
06-29	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	GL
06-29	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	AQ

AB Science Stock OTC Markets

Stocks

ABSCF

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Course Extremes

Managers and Directors: AB Science

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Income Statement and Estimates

Quarterly revenue - Rate of surprise

07-13	Bourse : Go West pour Stellantis, Apple se fâche contre OpenAI, Akzo courtisé
07-13	Wall Street ne chômera pas le 14 juillet
07-10	AB Science rationalise son portefeuille et se recentre sur deux molécules
07-10	AB Science fait le point sur son programme clinique avec l’arrêt de certaines études cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques
07-08	Stéphane Ledermann prend les rênes d'AB Science en tant que PDG

Current year	1.12	1.37
1 year	1.12	1.45
3 years	0	4.46
5 years	0	18.78
10 years	0	26.7

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	2026-07-06
Laurent Guy DFI	Director of Finance/CFO	-	2009-11-19
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	2018-03-31

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	2001-07-10
Patrick Moussy BRD	Director/Board Member	-	2011-09-19
Cécile de Guillebon BRD	Director/Board Member	64	2021-06-26

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	-.--%	-.--%	-	-	52.03M
MERCK & CO., INC.	+0.96%	+3.12%	+56.19%	+15.47%	312B
MERCK KGAA	+1.97%	-2.28%	+25.65%	-11.82%	66.59B
HALOZYME THERAPEUTICS, INC.	-0.99%	+2.64%	+35.25%	+81.44%	9.32B
KYOWA KIRIN CO., LTD.	-1.20%	-1.89%	+2.89%	-4.93%	8.53B
SK BIOPHARMACEUTICALS CO., LTD.	-1.03%	-1.79%	-24.11%	-10.07%	4.1B
BETTA PHARMACEUTICALS CO., LTD.	+0.38%	-9.58%	-5.58%	+22.13%	3.76B
YUHAN CORPORATION	+0.86%	+1.01%	-43.84%	+10.01%	3.51B
SUPERNUS PHARMACEUTICALS, INC.	-1.94%	-1.66%	+43.68%	+53.35%	2.78B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-2.81%	-6.33%	+5.13%	-9.94%	2.19B
Average	-0.38%	-0.87%	+10.58%	+16.18%	45.85B
Weighted average by Cap.	+0.97%	+3.06%	+47.12%	+12.02%

	2026 *	2027 *
Net sales	1.2M 1.37M 1.11M 1.02M 1.93M 132M 1.96M 13.27M 5.19M 64.67M 5.14M 5.03M 223M	1.3M 1.48M 1.21M 1.11M 2.09M 143M 2.12M 14.38M 5.63M 70.05M 5.57M 5.45M 242M
Net income	-	-
Net Debt	-	-